Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes

D A Cameron, J C Keen, J M Dixon, C Bellamy, A Hanby, T J Anderson, W R Miller

Research output: Contribution to journalArticlepeer-review

Abstract

Despite knowledge of oestrogen receptor status, it is not always possible to predict which breast cancers will respond to tamoxifen. We have previously reported that decreased expression of Bcl-2 and/or Ki-S1 were associated with tumour response to neo-adjuvant tamoxifen in 50 elderly women with oestrogen receptor (ER)-positive breast cancer. In this study, we confirm that the expression of Bcl-2 and Ki-S1 are surrogates for the frequency of apoptosis and mitosis respectively, within these untreated breast cancers, with an inverse relationship between Bcl-2 expression and the apoptotic index (P
Original languageEnglish
Pages (from-to)845-51
Number of pages7
JournalEuropean Journal of Cancer
Volume36
Issue number7
Publication statusPublished - May 2000

Keywords

  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm
  • Apoptosis
  • Breast Neoplasms
  • Cell Division
  • DNA Topoisomerases, Type II
  • DNA-Binding Proteins
  • Female
  • Humans
  • Immunohistochemistry
  • Mitosis
  • Nuclear Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tamoxifen
  • Time Factors
  • Tumor Markers, Biological

Fingerprint

Dive into the research topics of 'Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes'. Together they form a unique fingerprint.

Cite this